Verici Dx Plc
LSE:VRCI

Watchlist Manager
Verici Dx Plc Logo
Verici Dx Plc
LSE:VRCI
Watchlist
Price: 0.725 GBX
Market Cap: £11m

Operating Margin

-547.4%
Current
Improving
by 15 059%
vs 3-y average of -15 606.4%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-547.4%
=
Operating Income
$-7.8m
/
Revenue
$1.9m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-547.4%
=
Operating Income
GBX-7.8m
/
Revenue
$1.9m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Verici Dx Plc
LSE:VRCI
11m GBP
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
394.7B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44.1B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.5B USD
Loading...

Market Distribution

Lower than 91% of companies in the United States of America
Percentile
9th
Based on 14 112 companies
9th percentile
-547.4%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Verici Dx Plc
Glance View

Market Cap
11m GBX
Industry
Biotechnology

Verici Dx Plc operates as a developer of advanced clinical diagnostics in organ transplant. The company is headquartered in Franklin, Tennessee and currently employs 8 full-time employees. The company went IPO on 2020-11-03. The principal activity is the development of prognostic and diagnostic tests for kidney transplant patients. The firm's kidney transplant assays use sequencing that defines a personalized risk-profile of each patient over the course of the transplant journey. The firm develops tests to understand how a patient is responding to organ transplants. The firm's products include Clarava and Tuteva. Clarava is a pre-transplant prognosis for the risk of early acute rejection (EAR). Tuteva is a post-transplant diagnostic focused upon acute cellular rejection (ACR), including sub-clinical rejection. The firm's subsidiary is Verici Dx Inc.

VRCI Intrinsic Value
0.826 GBX
Undervaluation 12%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-547.4%
=
Operating Income
$-7.8m
/
Revenue
$1.9m
What is Verici Dx Plc's current Operating Margin?

The current Operating Margin for Verici Dx Plc is -547.4%, which is above its 3-year median of -15 606.4%.

How has Operating Margin changed over time?

Over the last 2 years, Verici Dx Plc’s Operating Margin has increased from -75 987.7% to -547.4%. During this period, it reached a low of -75 987.7% on Jun 30, 2023 and a high of -143.4% on Jun 30, 2024.

Back to Top